EXHIBIT 10.1

                            SHARE TRANSFER AGREEMENT

            This SHARE TRANSFER AGREEMENT (this "AGREEMENT"),  dated January 20,
2006 and effective  December 31, 2005 (the "EFFECTIVE DATE"), by and between Par
Pharmaceutical  Companies,  Inc.  (formerly known as  Pharmaceutical  Resources,
Inc.),  a  Delaware  corporation  (the  "SELLER"),  and  Dr.  Arie  Gutman  (the
"PURCHASER").

            WHEREAS, the Seller owns all of the issued and outstanding shares of
capital stock (the "SHARES") of FineTech  Laboratories Ltd., a company organized
under the laws of the State of Israel ("FINETECH"); and

            WHEREAS,  the Seller  determined  prior to the  Effective  Date that
FineTech is not  profitable  and,  therefore,  the Seller desires to abandon its
interest  therein and transfer the Shares to the  Purchaser,  and the  Purchaser
desires to acquire  from the  Seller,  subject to the terms and  conditions  set
forth herein, the Shares for the consideration set forth herein; and

            NOW,   THEREFORE,   in   consideration   of  the  premises  and  the
representations,  warranties, covenants and agreements set forth herein, and for
other good and valuable  consideration (the receipt and sufficiency of which are
hereby acknowledged), the Seller and the Purchaser hereby agree as follows:

            1.  TRANSFER AND ACQUISITION; CLOSING.

      1.1 TRANSFER AND ACQUISITION OF THE SHARES. Subject to the terms set forth
herein,  the Purchaser hereby agrees to acquire from the Seller,  and the Seller
hereby  agrees to  transfer  to the  Purchaser,  the Shares "as is" and  without
representation  or  warranty  of  any  kind,  express  or  implied,   except  as
specifically  set forth  herein.  As soon as  practicable  after the Closing (as
defined  below),  the Seller shall deliver to the Purchaser  stock  certificates
evidencing the Shares.

      1.2 THE CLOSING. The closing of the transfer and acquisition of the Shares
hereunder (the  "CLOSING")  shall take place effective as of the Effective Date.
The Closing shall occur remotely via the exchange of documents and signatures.

            2.  REPRESENTATIONS  AND WARRANTIES OF THE SELLER. The Seller hereby
represents and warrants to the Purchaser that the Seller owns,  beneficially and
of record, all of the Shares free and clear of any liens or other  encumbrances.
The Seller is hereby transferring to the Purchaser all of the Seller's title and
ownership in and to the Shares "as is" without representation or warranty of any
kind (including,  with respect to FineTech's business,  condition,  prospects or
otherwise and the Purchaser hereby acknowledges that no such  representations or
warranties have been made), express or implied, except as specifically set forth
herein.

            3.  REPRESENTATIONS  AND WARRANTIES OF THE PURCHASER.  The Purchaser
hereby represents and warrants to the Seller that the Purchaser (a) is acquiring
the Shares solely for its own account for the purpose of investment and not as a
nominee  or agent for any other  person  and not with a view to, or for offer or
sale  in  connection  with,  any  distribution  thereof,  (b) is an  "accredited



investor" within the meaning of Rule 501(a)(4), (4) or (6) of Regulation D under
the  Securities  Act of 1933,  as  amended,  (c) is not  relying on the  Seller,
FineTech or any of their respective  employees,  representatives  or agents with
respect  to  the  legal,  tax,  economic  and  related  considerations  as to an
investment in the Shares,  (d) has engaged legal counsel in connection  herewith
and such counsel is not  Kirkpatrick  & Lockhart  Nicholson  Graham LLP, (e) has
relied  solely  on its  independent  investigation  and the  advice of its legal
advisors and (f) has such  knowledge  and  experience  in financial and business
matters that the Purchaser is capable of  evaluating  the merits and risks of an
investment  in the  Shares  and is capable of  protecting  the  Purchaser's  own
interest in connection with the transfer and acquisition of the Shares.

            4.  CERTAIN TAX MATTERS. The Seller shall prepare and file, or cause
to be prepared and filed, all tax returns of FineTech for all tax periods ending
on or prior to the Effective  Date,  and pay or cause to be paid,  when due, all
taxes owing by FineTech for all periods  covered by such tax returns  (except to
the extent such taxes were reserved for on  FineTech's  balance sheet or accrued
by FineTech in the ordinary course of business). Notwithstanding anything to the
contrary  contained in this Agreement or provided by applicable  law, all sales,
real property,  stock or other transfer,  or similar taxes arising directly from
the  consummation of the transactions  contemplated  hereby shall be paid by the
Seller. The Seller shall prepare and file all tax returns in connection with all
such sales and transfer taxes. The Purchaser shall have provided the Seller,  in
properly  completed form, any exemption  certificates with respect to such sales
and transfer taxes that may be executed by the Purchaser  under  applicable law.
From and after the Effective  Date, the Seller and the Purchaser shall cooperate
with  each  other  and  provide  each  other  with  such  assistance  (including
testimony) as may  reasonably be requested by either of them in connection  with
the  preparation  of any tax  return  or any audit or other  examination  by any
taxing governmental entity, any judicial or administrative  proceedings relating
to any liability for taxes under this Agreement,  or any claims for refunds. The
party  requesting  assistance  hereunder  shall  promptly  reimburse  the  party
providing  assistance  for all  reasonable  third-party  out-of-pocket  expenses
incurred in providing such assistance.

            5.  ACCELERATION  OF CERTAIN STOCK  OPTIONS.  The Seller's  board of
director's  Compensation and Stock Option Committee shall accelerate the vesting
of all of the unvested stock options set forth on EXHIBIT A hereto,  which shall
be fully vested on the date hereof and exercisable, pursuant to the terms of the
award  agreement  evidencing  the  Seller's  grant  thereof,  by the  respective
optionees  set forth  opposite such options on EXHIBIT A within thirty (30) days
after the date hereof.

            6.  MISCELLANEOUS.

      6.1 EXPENSES;  OPERATING COSTS AND EXPENSES.  The Seller and the Purchaser
shall each bear their own expenses with respect to this Agreement. The Purchaser
shall be  responsible  for all costs and  expenses  related to the  operation of
FineTech after the Effective Date.

      6.2 SEVERABILITY.  The invalidity or  unenforceability of any provision of
this  Agreement  shall not affect the  validity or  enforceability  of any other
provision of this Agreement.


                                     - 2 -



      6.3 BINDING EFFECT;  GOVERNING LAW AND JURISDICTION.  This Agreement shall
be binding upon the parties and their respective successors and assigns, and all
matters  arising in  connection  with this  Agreement  shall be governed by, and
construed  and enforced in accordance  with,  the laws of the State of New York.
The parties hereby irrevocably  consent to the nonexclusive  jurisdiction of the
courts of the State of New York and of any federal  court  located in such State
in connection  with any action or proceeding  arising out of or relating to this
Agreement.

      6.4 NOTICES.  All   notices,   requests,   demands,   waivers   and  other
communications  required or permitted to be given under this Agreement  shall be
in writing and shall be deemed to have been duly given if delivered  personally,
sent by  facsimile  transmission  or  reputable  overnight  courier,  or  mailed
(certified or registered mail, return receipt requested):

      If to the Seller, to:

            Par Pharmaceutical Companies, Inc.
            300 Tice Blvd.
            Woodcliff Lake, NJ 07677
            Attention: General Counsel
            Telecopier:  (201) 802-4215

      With a copy (which copy shall not constitute notice) to:

            Kirkpatrick & Lockhart Nicholson Graham LLP
            599 Lexington Avenue
            New York, New York 10022
            Attn: R. King Milling Jr., Esq.
            Telecopier: (212) 536-3901

      If to the Purchaser, to:

            Dr. Arie Gutman
            FineTech Laboratories Ltd.
            33 Hanarkissim  Street
            Science Park Nesharim
            Nesher 36601 Israel
            Telecopier:  011 (972) 524 733 833

or to such  other  person or  address  as any party  shall  specify by notice in
writing to the other party.  All such notices,  requests,  demands,  waivers and
communications  shall be deemed to have  been  received  on the date on which so
hand-delivered,  telecommunicated  or delivered  by overnight  courier or on the
fifth (5th)  business day  following  the date on which so mailed,  except for a
notice of change of address, which shall be effective only upon receipt thereof.

      6.5 COMPLETE  AGREEMENT.  This Agreement  (including the exhibits  hereto)
constitutes the entire  agreement and  understanding  of the parties hereto with
respect to the subject  matter hereof and  supersedes  all prior  agreements and
understandings relating to such subject matter.


                                     - 3 -



      6.6 AMENDMENTS  AND  WAIVERS.  This Agreement may be amended or terminated
and the observance of any term of this Agreement may be waived (either generally
or in a particular instance and either retroactively or prospectively), with the
written consent of the Seller and the Purchaser.  No waivers of or exceptions to
any  term,  condition  or  provision  of  this  Agreement,  in any  one or  more
instances,  shall be deemed  to be, or  construed  as, a further  or  continuing
waiver of any such term, condition or provision.

      6.7 COUNTERPARTS;  FACSIMILE SIGNATURES. This Agreement may be executed in
any number of counterparts, each of which shall be deemed to be an original, and
all of which shall  constitute one and the same document.  This Agreement may be
executed by facsimile signatures.

      6.8 ASSIGNMENT;  CHANGE OF CONTROL.  Neither this Agreement nor any of the
rights,  interests  or  obligations  hereunder  may be assigned or  delegated by
either the Seller or the Purchaser by operation of law or otherwise  (including,
without  limitation,  by way of Purchaser's  estate),  without the prior written
consent  of the  other  party  hereto  and  any  such  purported  assignment  or
delegation shall be null and void AB INITIO; PROVIDED, HOWEVER, no consent shall
be required for the Seller to assign this Agreement to any of its affiliates. As
a condition to any permitted assignment, the assignee shall agree to be bound by
the terms and provisions of this Agreement.

      6.9 SECTION  HEADINGS  AND  REFERENCES.  The section  headings are for the
convenience of the parties and in no way alter, modify, amend, limit or restrict
the contractual obligations of the parties. Any reference in this agreement to a
particular  section or subsection shall refer to a section or subsection of this
Agreement, unless specified otherwise.

      6.10 FURTHER  ASSURANCES.  From time  to time  after the  Closing,  at the
request  of one of the  parties  hereto  and at  the  expense  of the  party  so
requesting,  the Seller and the  Purchaser  shall  execute  and  deliver to such
requesting  party such  documents and take such other action as such  requesting
party  may  reasonably  request  in order to  consummate  more  effectively  the
transactions contemplated hereby, including,  without limitation,  the filing of
applicable taxes with the appropriate governmental agencies.



                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]



                                     - 4 -



      IN WITNESS  WHEREOF,  the parties hereto have executed this Share Transfer
Agreement as of the date first above written.


PAR PHARMACEUTICAL COMPANIES, INC.




By:______________________________
     Name:
     Title:





_________________________________
DR. ARIE GUTMAN